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Abstract
A European collaboration on Charcot-Marie-Tooth type 1 (CMT1) disease 
and hereditary neuropathy with liability to pressure palsies (HNPP) was estab­
lished to estimate the duplication and deletion frequency, respectively, on 
chromosome 17pl 1.2 and to make an inventory of mutations in the myelin 
genes, peripheral myelin protein 22 (PMP22), myelin protein zero (MPZ) and 
connexin 32 (Cx32) located on chromosomes 17pl 1.2, Iq21-q23 andX ql3.1 , 
respectively. In 70.7% of 819 unrelated CMT1 patients, the 17p11.2 duplica­
tion was present. In 84.0% of 156 unrelated HNPP patients, the 17p 11.2 dele­
tion was present. In the nonduplicated CMT1 patients, several different muta­
tions were identified in the myelin genes PMP22, MPZ and Cx32.
Introduction
The hereditary motor and sensory neuropathies 
(HMSNs) are a clinically heterogeneous group of periph­
eral neuropathies, characterized by slowly progressive 
weakness and atrophy of the distal limb muscles [1]. The 
prevalence of all types has been estimated at 1 in 10,000 
[2]. HMSN type I or Charcot-Marie-Tooth disease type 1 
(CMT1) is the most common form. Clinically, CMT1 is 
characterized by pes cavus, reduced or absent deep-ten- 
don reflexes, and hypertrophic nerves. The age of onset of 
the symptoms is the first or second decade, with a consid­
erable variation among CMT1 patients ranging from 
almost no symptoms to severe weakness, atrophy, and 
foot deformity. However, all CMT1 patients have severe­
ly reduced nerve conduction velocities (NCVs) and seg­
mental de- and remyelination on nerve biopsy.
Positional cloning has shown that CMT1 is genetically 
heterogeneous with at least four distinct loci. The major 
autosomal dominant subtype CMT1A is linked to chro­
mosome 17pll.2  [3, 4], a minor subtype CMT1B is 
linked to chromosome 1 in the region Iq22-q23 [5, 6] and 
a third, still unassigned subtype CMT1C is not linked to 
either of these loci [7]. An X-linked dominant locus was
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mapped to chromosome Xql3 [8]. In the majority of the 
CMT1A patients, the disease is associated with a tandem 
DNA duplication of 1.5 Mb [9, 10]. This duplication is 
also the cause of the disease in the majority of the sporadic 
CMT1 cases [11, 12]. The peripheral myelin protein 22 
gene (PMP22) was found to be located within the CMT1A 
duplication, suggesting that overexpression of this gene 
causes the CMT1A disease phenotype [13-16]. Point mu­
tations in PMP22 in nonduplicated CMT1A patients con­
firmed the direct role of the gene in the CMT1A disease 
process [ 17-20]. The myelin protein zero gene (MPZ), the 
major myelin gene of the peripheral nerve, has been 
assigned to chromosome 1 in the region where CMT1B 
was previously mapped by linkage analysis studies [5]. 
Several distinct mutations in MPZ cosegregating with the 
disease identified MPZ as the CMT1B gene [21-26]. The 
gene encoding connexin 32 (Cx32), a gap junction pro­
tein, was found to be located in the CMTX candidate 
region at Xql3.1. Mutations were found in 24 out of 27 
X-linked CMT1 families [27-30], The expression of Cx32 
in the peripheral nerve was not known before [27].
Hereditary neuropathy with liability to pressure pal­
sies (HNPP), also called tomaculous neuropathy, is char­
acterized by periodic episodes of numbness and palsies 
that follow relatively minor compression or trauma to the 
peripheral nerves. Electrophysiology may reveal reduced 
motor and sensory NCVs in clinically affected patients 
and asymptomatic carriers. On nerve biopsy, tomaculae 
or sausage-like structures are present. HNPP is inherited 
as an autosomal dominant trait [31]. The disease is usual­
ly associated with a deletion in chromosome 17pl 1.2 [32], 
In the vast majority of cases, the deletion comprises all 
markers that are duplicated in CMT1A. Furthermore, the 
duplication and the deletion arise from the same unequal 
crossing-over event at the CMT1A-REP site, a repeat 
sequence flanking the CMT1A region [33, 34]. Therefore, 
the CMT1A duplication and the HNPP deletion are 
reciprocal mutations. A decreased dosage of PMP22 is a 
possible cause of HNPP. This hypothesis is supported by 
the fact that a nondeleted HNPP patient was identified 
who carried a 2-bp deletion in PMP22 causing early ter­
mination of transcription [35].
To estimate the frequencies of the CMT1A duplication 
and the HNPP deletion in Europe, and to make an inven­
tory of the different mutations in PMP22, MPZ, and 
Cx32, the data of several European research centers 
were pooled. A first European Neuromuscular Center 
(ENMC)-sponsored workshop on hereditary motor and 
sensory neuropathies was organized in Baam, The Neth­
erlands, in May 1991 [36]. Here it was decided to estab­
lish diagnostic criteria for HMSN type I, and to define the 
requirements for individuals to be included in a linkage 
analysis [36]. Briefly, these criteria are: (1) slowly progres­
sive symmetrical muscle wasting and weakness, predomi­
nantly of the distal part of the lower limbs; (2) severely 
decreased motor median NCVs (<30 m/s), absence or 
marked decrease of sensory nerve action potentials 
(SNAPs) in the lower limbs and/or a sensory nerve biopsy 
consistent with a diagnosis of demyelinating neuropathy, 
and (3) pedigree consistent with autosomal dominant 
inheritance. The low cutoff NCV value of 30 m/s was used 
since such low NCV values have been observed only in 
CMT1 patients, ensuring that only families with a CMT1 
phenotype would be ascertained in the linkage analysis 
studies. At this meeting, a European CMT consortium 
group was also formed. A second ENMC-sponsored work­
shop was organized in Den Dolder, The Netherlands, in 
December 1992 [37]. Members of the CMT consortium 
group involved in DNA diagnosis of CMT patients were 
sent a questionnaire to assess the frequency and the size of 
the 17pl 1.2 duplication in their patients with a CMT1 
phenotype, to determine the frequency of new mutation 
cases in sporadic CMT 1 patients, and to evaluate possible 
screening methods for the CMT 1 duplication. Only data 
obtained on patients with a well-defined phenotype were 
included. Selection criteria for the familial cases were as 
defined at the first workshop. The clinical and electro- 
physiological criteria were the same for the sporadic 
CMT1 patients. In addition, both parents had to be clini­
cally and electrophysiologically normal and analyzed for 
the duplication, and paternity of the patients had to be 
confirmed. Data from 20 laboratories in 11 countries 
were retained in the final analysis, resulting in a duplica­
tion frequency of 84.6% of the familial CMT1 cases (total 
of 273 families), and a de novo duplication frequency of 
93% (total of 28 patients) [37]. In 9 of the de novo dupli­
cations, the parental origin could be deduced: all 9 were 
paternally derived [ 12].
At the 26th annual meeting of the European Society of 
Human Genetics in Paris, France, in June 1994, a meet­
ing of the European CMT consortium group was orga­
nized to update the data on the duplication frequency in 
CMT 1 patients, to make a first inventory of the type and 
frequency of mutations in PMP22, MPZ, and Cx32, and 
to estimate the deletion frequency in patients with HNPP. 
All members of the CMT consortium group were asked to 
complete a questionnaire concerning duplication, dele­
tion, and mutation screening of CMT1 and HNPP pa­
tients. The CMT1 patients had to fulfil all clinical and 
electrophysiological criteria as defined at the first work-
26 E u rJ  H um  Genet 1996;4:25-33 Nelis/Van Broeckhoven
shop. However, since we wanted to ascertain all CMT1 
patients, a cutoff value of 38 m/s for the motor median 
nerve was used, as proposed by Harding and Thomas [38] 
on the basis of motor median NCV measurements in 170
Results
CMT1A Duplication Frequency 
A total of 881 unrelated CMT1 patients were tested for
CMT patients [38], Furthermore, no restrictions were the presence of the CMT1A duplication by one or more of
made with respect to patients’ family history, since we the techniques mentioned above. 819 patients were infor-
also wanted to assess the duplication/deletion frequencies mative for the duplication analysis, i.e. 579 patients were
in clinically isolated and genetically sporadic cases. For duplicated and 240 patients were not. The remaining 62
HNPP patients, no consensus diagnosis was available and patients were uninformative. These data resulted in a
thus each center used their own diagnostic criteria. We duplication frequency of 70.7% (table 1). Part of the dupli-
received the results from 28 centers, the data were com- cation screening results of the individual participating cen-
piled and are discussed in this paper.
Methods
Duplication and Deletion Screening
The most common technique used in the different participating 
centers to detect the duplication was the scoring of three alleles or 
dosage differences on Southern blot hybridization: intensities of het­
erozygous RFLP alleles were visually compared one versus the oth­
er. Subclones [39] of the following markers, free of repetitive se­
quences, were provided by the European CMT consortium group: 
pVAW409Rl, pVAW409R3, pVAW412R3, or pEW401. One or 
more of these markers, or the PMP22 probe pl32G8Rl [13], were 
used in the analysis. The scoring of triple alleles was also done using 
the microsatellitc markers RM1l-GT and Mfd41 [10, 40]. In a few 
laboratories, the duplication was identified by quantification of 
alleles of fluorescent-labeled microsatellite markers RM11-GT, 
Mfd41, AFM191xhl2, AFM317ygl, and AFM200ybl2, using ABI 
GENESCAN 672 software (Applied Biosystems, Foster City, Calif., 
USA) [41, 42]. A few centers used additional techniques: fluores­
cence in situ hybridization (FISH) or pulscd-field gel electrophoresis 
(PFGE). FISH analysis detects three spots of a marker located within 
the CMT1A region compared to two spots of a marker located out­
side the duplication [10]. With PFGE, a novel junction fragment of 
500 kb can be detected in DNA digested with different rare cutter 
restriction enzymes such as iStodl, Fspl, oivlM, and hybridized with 
the marker pVAW409R3 or probes from the CMT1A-REP region
[10,15,33, 39].
Similar methods were used to detect the deletion in HNPP 
patients: scoring of loss of alleles on Southern blot hybridization or 
microsatellite markers and FISH analysis. In this study, PFGE was 
not used in the diagnosis of HNPP, although it is now possible to 
detect junction fragments in HNPP patients with markers from the 
CMT IA-REP region [19, 34, 43, 44].
Mutation Analysis
The techniques used for mutation screening in CMT1 and HNPP 
were single-stranded conformation polymorphism (SSCP) analysis, 
heteroduplcx analysis or direct sequencing of the coding regions of 
the myelin genes PMP22, MPZ, or Cx32, SSCP and hcteroduplex 
analysis do not detect all the mutations. The sensitivity of SSCP and 
heteroduplex analysis is estimated at 80% [45], Direct sequencing 
should reveal all mutations localized in the coding region of the 
genes. However, since this technique is very time-consuming and 
expensive, it was not routinely used in the DNA diagnostic laborato­
ries.
ters have been published elsewhere [9, 39, 46-54]. Only 6 
out of 579 (1.0%) patients were found to have a smaller 
duplication. One of these cases was described by Palau et al. 
[12]. The CMT1A duplication frequency varied signifi­
cantly between the different centers. The highest frequency 
was 100.0%, the lowest 34.3% (table 1). In principle, the 
duplication frequencies could be biased towards higher fre­
quencies if some of the centers would have included related 
CMT1 patients. However, to the best of our knowledge, the 
patients under study were unrelated, since the different 
centers contributed only 1 patient sample per CMT 1 fami­
ly. Also, the differences in frequency did not seem to reflect 
a different ethnic origin, since high and low frequencies 
occurred in the same country. However, in more isolated 
populations, like northern Sweden, the low duplication fre­
quency (37.5%) could be caused by a relatively higher fre­
quency of recessive CMT1 cases [51],
The duplication frequency of the familial cases, i.e. 
cases with at least one other known CMT 1 patient in the 
family, was 75.9% (477/628). If we selected only the prov­
en autosomal dominant cases, the duplication frequency 
was 85.2% (table 1). When we also included the dominant 
cases, i.e. cases belonging to families without male-to-male 
transmission, the duplication frequency decreased to 
78.4%, because in the latter group, the duplication fre­
quency was only 63.1 % (111/176). An explanation for this 
low duplication frequency could be that this group of dom­
inant cases also comprises patients with X-linked CMT1.
In clinically isolated cases, i.e. cases which had no 
family history of the disease or cases for which data on 
family history were not available, it was 53.4% (102/191). 
If only genetically sporadic cases were considered, i.e. 
cases with both parents clinically and electrophysiologi- 
cally normal, analyzed for the duplication and paternity 
confirmed, a de novo duplication was observed in 76.5% 
of the cases (table 1). Some of the individual participating 
centers have published their data elsewhere [11, 12, 55]. 
The de novo duplication cases represent 6.7% of the total 
number of duplicated CMT1 patients (39/579).
Mutation Frequencies in CMT I and HNPP
Neuropathies
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Table 1. Patients tested for the CMT1A duplication and the HNPP deletion
Center Duplication frequency in CMT1, % 
total AD de novo
Deletion frequency in HNPP, %
%
total AD de novo
Turku, Finland 84.0(25) 100.0(5) 50.0 (2) 100.0 (20) 100.0 (6) —
Umea, Sweden 37.5 (24) 100.0(9) —
Aarhus, Denmark 54.5(11) 62.5 (8) 100.0 (1)
Aberdeen, UK 60.0(15) 100.0 (2) 100.0 (1) —
Manchester, UK 77.8(18) 85.7(14) —
London, UK 69.2 (26) 66.7 (21) 100.0 (1)
Cardiff, UK 75.8(33) 75.0(32) 100.0 (1)
Nijmegen, The Netherlands 70.8 (24) 76.2 (21) 100.0 (1)
Loverval, Belgium 44.4(18) 57.1(7) — 100.0 (1) 100.0 (1) —
Antwerp, Belgium 69.7 (66) 73.7(19) 83.3(6) 100.0 (11) 100.0(4) 100.0 (1)
Heidelberg, Germany 100.0(3) 100.0(3) —
Bonn, Germany 81.5(27) 50.0 (2) — 50.0 (2) — —
Düsseldorf, Germany 81.8(11) — — 100.0 (2)
Leipzig, Germany 100.0(9) — —
Erlangen, Germany 61.1(18) 50.0 (4) 0.0 (1) 100.0 (1) 100.0 (1) —
Lyon, France 72.9 (155) 98.1 (104) 100.0 (11) 69.6 (23) 100.0(15) 100.0 (1)
Paris, France 76.1 (67) 89.8 (49) 100.0(3) 100.0(13) 100.0(13) —
Bern, Switzerland 76.5(17) 81.8(11) —
Lausanne, Switzerland 100.0 (10) 100.0 (1) — 100,0 (1) — —
Genova, Italy 97.1 (35) 96.7(30) 100.0(5) 100.0 (11) 100.0 (6) —
Padova, Italy 73.4 (64) 83.3 (24) 100.0(5) 100.0 (1) 100.0 (1) —
Cagliari, Italy 62.5(8) 50.0 (6) —
Bari, Italy 65.9(41) 192  (24) 11.1 (9) 87.5 (8) 100.0(3) 66.7 (3)
Barcelona, Spain 34.3(35) 28.6(7) —
Valencia, Spain 67.3 (49) 100.0 (12) 85.7 (7) 87.5 (8) 100.0(3) —
Athens, Greece 40.0(16) 30.0(10) — 100.0 (2) 100.0 (2) —
Kfar Saba, Israel 85.0 (40) 93.3(15) —
Total 70.7 (819) 85.2(398) 76.5(51) 84.0(156) 87.6 (97) 85.7 (7)
Values in parentheses are the total number of patients informative in the duplication/deletion screening. AD = 
autosomal dominant.
HNPP Deletion Frequency
162 HNPP patients were screened for the deletion. 156 
patients were informative for the deletion analysis, i.e., 
131 patients had the deletion, 25 were not deleted, while 
the remaining 6 patients were not informative. These data 
resulted in an overall deletion frequency of 84.0% in the 
HNPP patients. Deletion screening results of some indi­
vidual participating centers have been published [44, 56- 
59]. 5 out of 131 (3.8%) of the deleted HNPP patients had 
a smaller deletion; 1 of these patients is described by Cha­
pón et ah [submitted].
The deletion frequency in the familial cases was 86.1% 
(105/122), that in the proven autosomal dominant cases 
was 87.6% (table 1), and in the dominant cases 89.5% 
(17/19). These comparable deletion frequencies suggest
that an X-linked dominant form of HNPP is rather 
unlikely.
The deletion frequency in the clinically isolated cases 
was 76.5% (26/34). In 85.7% of the genetically sporadic 
cases, a de novo deletion was present (table 1). The de 
novo deletion cases represent 4.6% (6/131) of the total 
number of deleted HNPP patients.
Mutations in Myelin Genes
Mutation screening of the PMP22, MPZ, and Cx32 
genes was performed in 13 of the participating centers in 
40.8% (98), 44.6% (107) and 15.0% (36), respectively, of 
the nonduplicated CMT1 patients. In 3 out of 98 (4.1%) 
patients, a sequence variation in PMP22 was detected by 
SSCP analysis. In one of these patients, the mutation has
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Table 2. CMT1 and HNPP mutations
Disease Gene
CMT1 PMP22
MPZ
Cx32
HNPP PMP22
Exon/codon Nucleotide change Type Effect on
coding
sequence
Center Ref«
IVS3 +1 T G gt^T G at 5' splice site — Antwerp, Belgium [20]
4/147 CTG->CGG missense Leu Arg Kfar Saba, Israel [63]
2/63 TCC-*TTC missense Ser-> Phe Lyon, France [64]
2/7 8a TCG TTG missense Ser -> Leu Antwerp, Belgium [26]
2/78 TCG-> TTG missense Ser —> Leu Lyon, France [65]
2/81 CAC -» CGC missense His -» Arg Cardiff, UK
3/86-89 8 bp replaced by 5 bp Turku, Finland [66]
3/101 T G G ^ T G C missense Trp-^Cys Lyon, France [65]
3/122 AAT -»AGT missense Asn -» Ser Lyon, France [67]
3/134 GAC -» AAC missense Asp -» Glu Antwerp, Belgium [25]
3/134 GACh >GAA missense Asp -» Asn Antwerp, Belgium [26]
4/154* T AC -> T AA nonsense Tyr-^stop Antwerp, Belgium [26]
4/163 GGG -> AGG missense Gly -> Arg Antwerp, Belgium
4/167 GGG AGG missense Gly Arg Cardiff, UK
4/181 TAC -> TAG nonsense Tyr stop Antwerp, Belgium [26]
6/221 insertion of GC frameshift — Erlangen, Germany [68]
6/223 deletion of 4 bp fra mesh ift Ser233del Genova, Italy [69]
2/15b CGG->TGG missense Arg->Trp Lübeck, Germany
2/15a CGG->TGG missense Arg->Trp Umeä, Sweden
2/15b CGG -> CAG missense Arg -» Gin Aberdeen, UK [28]
2/22 CGA -> C AA missense Arg -> Gin Aberdeen, UK
2/25a (x2) CTC TTC missense Leu Phe Antwerp, Belgium [70]
2/26 TCG TTG missense Ser-» Leu Antwerp, Belgium [70]
2/26a TCG -> TTG missense Ser -» Leu Antwerp, Belgium [70]
2/38b GTG ATG missense Val->Met Lübeck, Germany [30]
2/40 CGA GTA missense Ala —» V al Aberdeen, UK
2/56 CTC TTC missense Leu Phe Aberdeen, UK
2/60b TGC->TTC missense Cys -» Phe Aberdeen, UK [28]
2/72-73 deletion of C frameshift early stop Aberdeen, UK [28]
2/72—73b deletion of C frameshift early stop Aberdeen, UK [28]
2/87 CCA GCA missense Pro Ala Antwerp, Belgium [70]
2/87a CCA -» GCA missense Pro —^ Ala Antwerp, Belgium [70]
2/9 3a ATG -> GTG missense Met->Val Aberdeen, UK
2/139b GTG —> ATG missense Val-»Met London, UK
2/142b CGG -> TGG missense Arg->Trp Lübeck, Germany
2/208 GAG -> AAG missense Glu Lys Aberdeen, UK [28]
2/215b C G G T G G missense A rg^Trp Aberdeen, UK [28]
2/220 CGA -> TGA nonsense Arg -> stop Aberdeen, UK [28]
2/238 CGC -> CAC missense A r g His Antwerp, Belgium [70]
2/281 TCG -yTAG nonsense Ser —» stop Antwerp, Belgium [70]
2/?b deletion of 18 bp London, UK
2/?b deletion of 11 bp London, UK
IVS1 + 1 GCgt GCtt 5' splice site — Valencia, Spain
IVS = intervening sequence; x 2 = mutation observed in 2 unrelated CMT1 patients. 
a Patients not fulfilling the criteria defined by the European CMT consortium group or patients not informative for the duplication. 
b Patients from X-linked pedigrees.
*
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been identified by sequencing (table 2). A PMP22 muta­
tion was also identified by sequencing in a CMT1 patient 
with no altered SSCP pattern [20]. In MPZ, 14 sequence 
variations were observed by SSCP or heteroduplex analy­
sis in 107 patients (13.1%). 13 MPZ mutations have al­
ready been identified by sequencing (table 2). In addition, 
2 MPZ mutations were found in patients not included in 
table 1, since they did not fulfil the inclusion criteria (no 
NCV values were available, table 2). Screening of the 
Cx32 gene by SSCP analysis and sequencing revealed 10 
mutations in 36 patients (27.8%, table 2). A further 17 
mutations in Cx32 were identified, 6 in patients not ful­
filling all inclusion criteria of this study, 10 in proven X- 
linked families, and 1 in a patient not informative for the 
CMT1A duplication (table 2).
Eight out of the 25 (32.0%) nondeleted HNPP cases 
were screened for mutations in the PMP22 and MPZ 
genes. SSCP analysis revealed one sequence variation in 
exon 1 of PMP22 segregating with the disease in an auto­
somal dominant HNPP family. Sequencing identified a 
splice donor site mutation [Bort, pers. communj.
Discussion
In this European collaboration study on CMT1 and 
HNPP mutation frequencies, 70.7% of 819 unrelated 
CMT1 patients had the CMT1A duplication. A similar 
duplication frequency of 68% was found in a smaller 
study of 63 unrelated CMT1 patients from the USA [60]. 
The duplication frequencies in the familial cases was 
75.9%, in the clinically isolated cases 53.4%. The duplica­
tion frequency in the autosomal cases was 85.2%, that in 
genetically sporadic cases 76.5%. In 84.0% of the 156 
unrelated HNPP patients, the 17pl 1.2 deletion was 
present. The nonavailability of strict diagnostic criteria 
for HNPP hampered the evaluation of the results from 
the different centers. Consequently, the frequencies var­
ied widely among the different centers. The deletion fre­
quency in the familial cases was 86.1%, in the clinically 
isolated cases 76.5%. The deletion frequency in the auto­
somal cases was 87.6%, that in genetically sporadic cases 
85.7%. Only 1.0% of the duplicated CMT1 patients had a 
smaller duplication, while 3.8% of the HNPP patients had 
a smaller deletion. These numbers are possibly an under­
estimation of the real number of smaller duplications/ 
deletions, since not all smaller duplications/deletions may 
be recognized if not all markers of the CMT1A region 
were analyzed. However, a recent report demonstrates 
that the same 500-kb junction fragment was found in 512
CMT1A duplication patients [61], confirming that a 
smaller duplication/deletion seems to be a very rare event 
in CMT1A and HNPP disease. The fact that the duplica­
tion and the deletion comprised exactly the same region 
in the vast majority of the CMT1 and HNPP patients sup­
ported the hypothesis that the duplication/deletion arises 
from an unequal crossing-over event at the CMT1A-REP 
site, the repeat sequence flanking the CMT1A/HNPP 
region [33, 34], The high frequency of de novo duplica­
tion/deletion cases in CMT1A and HNPP suggests a rela­
tive high mutation rate at 17p 11.2, The high duplication/ 
deletion frequencies in CMT 1/HNPP patients indicate 
that the duplication/deletion screening is an important 
molecular genetic tool allowing a molecular diagnosis in 
the majority of these patients.
In 7.0% (62/881) of the CMT1 patients and 3.7% 
(6/162) of the HNPP patients, the duplication/deletion 
screening was not informative. The informativeness of 
the duplication/deletion screening depends on the detec­
tion method. The FISH and PFGE methods are 100% 
informative, but are not routinely used in most centers. In 
the Southern blot hybridization and microsatellite analy­
sis, the informativeness depends on the heterozygosity of 
the alleles. A method to partially solve this problem is to 
use a nonduplicated reference marker in the Southern blot 
hybridization to compare dosages in homozygous pa­
tients. In general, it is difficult to quantify PCR products, 
particularly when radioactive labeling is used. Therefore, 
in microsatellite analysis, the presence of the duplication 
is most reliably diagnosed if three alleles are present [60]. 
However, automated analysis of fluorescence-labeled mi­
crosatellite markers allows the identification of the dupli­
cation by quantification of the alleles [41,42].
Mutation screening of the CMT1 myelin genes in non­
duplicated CMT1 patients is not yet a routine technique 
in most laboratories. Only part of the nonduplicated 
CMT1 cases were screened by SSCP analysis and/or 
direct sequencing. Therefore an exact estimation of the 
frequency of CMT1 mutations cannot be made. Based on 
the total number of mutations in the CMT1 genes re­
ported here and by others, it is clear that mutations in 
Cx32 are more frequent than MPZ mutations, and that 
they are both much more frequent than PMP22 muta­
tions. Therefore, for diagnostic purposes, nonduplicated 
CMT1 patients should be screened first for mutations in 
Cx32 (unless male-to-male transmission occurred in the 
family) and then in MPZ, before screening for PMP22 
mutations. Eight of the 25 nondeleted HNPP patients 
were tested for mutations in PMP22 and/or MPZ. In 1 
patient, a splice donor site mutation in PMP22 was iden-
30 Eur J Hum  Genet 1996;4:25-33 Nelis/V an Broeckhoven
tified [Bort, pers. commun.]. Since not all HNPP patients 
had a deletion or a mutation in PMP22 and since linkage 
analysis in some of the nondeleted families excluded a 
large part of chromosome 17p [62], the data confirmed 
that HNPP is genetically heterogeneous with a locus on 
17pl 1.2 and at least one other locus still to be identified.
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